COVID-19 is an emerging, rapidly evolving situation.
What people with cancer should know: https://www.cancer.gov/coronavirus
Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
NCL News Archive
Wednesday, May 15, 2019
Identifying the Risk of Infusion Reactions
The NCL has just launched a new Technical Service to assess the potential for infusion reactions. Systemic administration of nanomedicines (and other therapies) have the potential to cause infusion reactions in patients, which often delays or halts their clinical translation. These reactions can manifest as fevers, chills, rigors, rashes, chest or back pain, or difficulty breathing, and, in... View Post
Tuesday, April 9, 2019
NANOBIOTIX Announces First Ever Radioenhancer to Receive European Market Approval
Former NCL Collaborator NANOBIOTIX recently announced European market approval for their formulation Hensify® (NBTXR3). Per the press release:
Hensify®(NBTXR3) received European market approval (CE mark) enabling commercialization in 27 European Union countries for the treatment of locally advanced soft tissue sarcoma Hensify®--a first-in-class radioenhancer--offers cancer patients an... View PostThursday, April 4, 2019
New Mechanistic Immunotoxicology Protocols
NCL's Immunology team has put together a series of new protocols which probe various immunotoxicology aspects of nanomedicines. The 7 new protocols have been published on the NCL Assay Cascade Protocols webpage and are available for download. They include:
ITA-26: Detection of Intracellular Complement Activation in Human T Lymphocytes
The complement... View Post
Tuesday, March 5, 2019
CRS Nanomedicine and Nanoscale Delivery Webinar
The Controlled Release Society’s (CRS) Nanomedicine and Nanoscale Delivery Focus Group will host their first webinar in March, given by NCL Director, Scott McNeil. This webinar will highlight the unique challenges of nanomedicine development, including the complex characterization requirements for these formulations and the hurdles of regulatory review. Having characterized more than 400... View Post
Tuesday, March 5, 2019
December 2018 Awardees Announced
The NCL solicits applications for the most promising cancer nanomedicine candidates for acceptance into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety,... View Post
Friday, February 1, 2019
Position Available: Research Associate, Physicochemical Characterization
The Nanotechnology Characterization Lab (NCL) provides nanotechnology formulation and characterization services for universities, the pharmaceutical industry and other government programs. Since our founding in 2004, the NCL has characterized more than 400 different nanomedicines for more than 100 organizations worldwide. We are currently seeking a Research Associate to join... View Post
Friday, February 1, 2019
Position Available: Scientist, Physicochemical Characterization
The Nanotechnology Characterization Lab (NCL) provides nanotechnology formulation and characterization services for universities, the pharmaceutical industry and other government programs. Since our founding in 2004, the NCL has characterized more than 400 different nanomedicines for more than 100 organizations worldwide. We are currently seeking a Scientist to join our... View Post
Friday, February 1, 2019
JoVE Publication on LAL Assay
Endotoxin testing has been one of the most commonly requested needs among nanotech researchers applying to the NCL. Dr. Marina Dobrovolskaia, Sr. Principal Scientist, has spent more than a decade studying the intricacies of endotoxin detection in nanoformulations. Much of her work has focused on assessing the pros and cons of the various detection methods and determining ways to overcome... View Post
Friday, October 26, 2018
Licensing Opportunity: Novel Scavenger Receptor A1-Targeted Macromolecular Prodrug Platform
Investigators at the NCL have developed a drug delivery platform that targets scavenger receptor A1, a receptor highly expressed in macrophages, monocytes, mast cells, and dendritic cells (myeloid lineages), as well as endothelial cells. The platform is based on the anionic polymer poly(L-lysine succinylated), which contains side chains with pendant carboxylic acids that allow conjugation of... View Post
Thursday, October 18, 2018
Changes to NCL Application Due Dates for 2019
Beginning in 2019 the NCL will accept applications twice per year, a change from previous years in which applications were accepted quarterly. The due dates for applications will be the first business days of March and September.
For those of you still hoping to apply this year, we are still accepting December applications this year, with the due date... View Post